The MAX study: A randomised phase II/III study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with untreated metastatic colorectal cancer

ABSTRACT: Primary objectives: Phase II stagePrimary Objective:• To determine the relative toxicity of the combination of capecitabine andbevacizumab and the combination of capecitabine, mitomycin C (MMC) andbevacizumab with that of capecitabine monotherapy. Phase III stagePrimary Objective:• To compare progression-free survival (PFS) on the three arms Primary endpoints: Phase II stagePrimary Endpoint: Treatment-related toxicity Phase III stagePrimary endpoint: Progression free survival (PFS)

DISEASE(S): Previously Untreated Metastatic Colorectal Cancer

PROVIDER: 2518837 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR